Carboplatin

Carboplatin is a chemotherapy drug widely used in cancer treatment. This article explores recent clinical trials investigating carboplatin’s effectiveness in various types of cancer, including ovarian, breast, and lung cancers. We’ll examine how carboplatin is being studied in combination with other drugs and as part of different treatment approaches to improve patient outcomes.

Introduction

Carboplatin is a chemotherapy medication used to treat various types of cancer. It belongs to a class of drugs called platinum-containing compounds or platinum coordination complexes[1]. Carboplatin works by interfering with the DNA in cancer cells, preventing them from dividing and growing.

This drug is sometimes referred to by brand names like Paraplatin[3]. It is typically administered intravenously (through an IV) in a hospital or clinic setting under the supervision of a healthcare professional.

Uses and Conditions Treated

Carboplatin is used to treat several types of cancer, including:

  • Metastatic prostate cancer: Advanced prostate cancer that has spread to other parts of the body[1]
  • Head and neck cancer: Cancers affecting areas like the mouth, throat, and voice box[2]
  • Breast cancer: Particularly HER2-positive breast cancer in combination with other drugs[3]
  • Non-small cell lung cancer (NSCLC): A common type of lung cancer[5]

Carboplatin is often used when cancers are advanced or have not responded to other treatments. It may be given as a first-line treatment or after other therapies have been tried.

How Carboplatin is Administered

Carboplatin is typically given as an intravenous (IV) infusion. The dosage and schedule can vary depending on the specific condition being treated and other factors. Some common administration details include:

  • Dosage often calculated based on body surface area or a measure called AUC (area under the curve)[3]
  • Usually given once every 3 weeks (21-day cycles)[1][3]
  • Infusion time can range from 15-60 minutes[2][3]
  • Treatment may continue for 4-6 cycles or longer, depending on response and side effects[3][5]

Combination Therapies

Carboplatin is often used in combination with other cancer treatments to enhance effectiveness. Some common combination therapies include:

  • Carboplatin + paclitaxel (Taxol): Used for various cancers including breast and lung cancer[3][5]
  • Carboplatin + docetaxel (Taxotere): Another combination for breast and other cancers[3]
  • Carboplatin + radiation therapy: Sometimes used for head and neck cancers[2]
  • Carboplatin + targeted therapies: Such as trastuzumab (Herceptin) for HER2-positive breast cancer[3]

Potential Side Effects

Like all chemotherapy drugs, carboplatin can cause side effects. Some common side effects may include:

  • Decreased blood cell counts: This can lead to increased risk of infection, anemia, and bleeding[2]
  • Nausea and vomiting: Often managed with anti-nausea medications[2]
  • Fatigue: Feeling very tired or weak[2]
  • Hair loss: May be partial or complete, usually temporary
  • Mouth sores: Also called mucositis[2]
  • Kidney function changes: Regular blood tests are done to monitor this[1]

Your healthcare team will monitor you closely for side effects and may adjust your treatment if needed. Some medications, like amifostine, are being studied to help reduce certain side effects of carboplatin and other chemotherapy drugs[2].

Efficacy and Outcomes

The effectiveness of carboplatin can vary depending on the type and stage of cancer being treated. Some measures of efficacy include:

  • Objective response rate (ORR): The percentage of patients whose tumors shrink or disappear with treatment[3]
  • Pathologic complete response (pCR): The absence of any detectable cancer cells after treatment, particularly important in breast cancer[3]
  • Progression-free survival: How long patients live without their cancer getting worse
  • Overall survival: How long patients live after starting treatment

Clinical trials continue to study carboplatin in various combinations and for different types of cancer to improve outcomes for patients.

Frequently Asked Questions

How long does carboplatin stay in your system?

Carboplatin can remain in your body for several days to weeks after treatment. However, the exact time can vary based on individual factors like kidney function. Your doctor can provide more specific information based on your situation.

Can I take other medications while on carboplatin?

It’s important to tell your healthcare team about all medications, supplements, and herbal products you’re taking. Some may interact with carboplatin. Always check with your doctor before starting or stopping any medications during your treatment.

How will I know if the carboplatin is working?

Your doctor will monitor your progress through regular check-ups, blood tests, and imaging scans. These will help determine how well the treatment is working. It’s important to attend all scheduled appointments and report any new symptoms or side effects to your healthcare team.

Glossary

  • Chemotherapy – A type of cancer treatment that uses drugs to destroy cancer cells
  • Intravenous (IV) – Administered directly into a vein
  • Metastatic – Cancer that has spread from its original site to other parts of the body
  • HER2-positive – A type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2
  • Neoadjuvant – Treatment given before the main treatment, usually to shrink a tumor
  • Pathologic complete response (pCR) – The absence of all signs of cancer in tissue samples after treatment
Drug NameCommon UsesAdministrationCommon Side Effects
Carboplatin (Paraplatin)Prostate cancer, head and neck cancer, breast cancer, lung cancerIV infusion every 3 weeksDecreased blood cell counts, nausea, fatigue, hair loss

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT03652493
  • [2]: https://clinicaltrials.gov/study/NCT00270790
  • [3]: https://clinicaltrials.gov/study/NCT02187744
  • [5]: https://clinicaltrials.gov/study/NCT04325698
Cancer Type Trial Focus Combination Therapies Key Outcomes Measured
Ovarian Cancer Elderly patients (70+ years), Stages III-IV Carboplatin + Paclitaxel (Taxol) Safety, Efficacy, Overall survival
Breast Cancer (HER2-positive) Neoadjuvant treatment, Early-stage Carboplatin + Docetaxel (Taxotere) + Trastuzumab Pharmacokinetics, Pathologic Complete Response, Objective Response Rate
Breast Cancer (Triple-negative) Neoadjuvant treatment, Stages II-III Carboplatin + Paclitaxel, followed by Epirubicin + Cyclophosphamide Pathologic Complete Response, Progression-free survival, Overall survival
Non-small Cell Lung Cancer Perioperative treatment, Stages I-II Carboplatin + Paclitaxel 3-year survival, Objective response rate
Medulloblastoma Standard risk in adults Carboplatin + Etoposide, followed by radiation therapy 1-year disease-free survival, Overall survival, Neurocognitive toxicity

Ongoing Clinical Trials on Carboplatin

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    1 1 1 1
    Austria Belgium Czechia Denmark France Germany +9
  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    1 1 1 1
    Austria Belgium France Germany Hungary Italy +3
  • A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

    Recruiting

    1 1 1
    France Germany Italy Poland Spain
  • A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium France Germany Italy The Netherlands +3
  • Comparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Germany
  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    1 1 1 1
    Austria Belgium France Germany Greece Hungary +5
  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Belgium Denmark France Germany Greece Hungary +6
  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    1 1 1 1
    Belgium France Germany Greece Italy Poland +3
  • A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

    Recruiting

    1 1 1
    France Germany Greece Italy Poland Spain
  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    1 1 1 1
    Austria Belgium Bulgaria Czechia Denmark France +11

Glossary

  • Carboplatin: A chemotherapy drug used to treat various types of cancer. It works by interfering with DNA replication in cancer cells, preventing them from dividing and growing.
  • AUC: Area Under the Curve, a measure used to determine the appropriate dose of carboplatin based on a patient's kidney function and other factors.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • HER2-positive breast cancer: A type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes cancer cell growth.
  • Triple-negative breast cancer: A type of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 protein, making it more difficult to treat with hormone therapies or HER2-targeted drugs.
  • Pathologic Complete Response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with cancer drugs.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free survival: The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival: The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • BRCA mutations: Inherited changes in the BRCA1 or BRCA2 genes that increase the risk of certain cancers, particularly breast and ovarian cancers.